Haridwar Today

Hemato-Oncology Testing Market: Growth Analysis, Projection & Industry Forecast to 2027

 Breaking News
  • No posts were found

Hemato-Oncology Testing Market: Growth Analysis, Projection & Industry Forecast to 2027

May 15
19:01 2023
Hemato-Oncology Testing Market: Growth Analysis, Projection & Industry Forecast to 2027
North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests
Browse 97 market data Tables and 32 Figures spread through 145 Pages and in-depth TOC on “Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User – Global Forecast to 2027

The global Hemato oncology testing market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.

Get Free Sample Copy of Report @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877

Key Market Players

The market is competitive. The major players operating in hemato oncology testing market are Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden), Cancer Diagnostics (US).


Abbott Laboratories was the leading player in the hemato-oncology testing market. In Abbott’s worldwide Diagnostics business, sales increased by 42.7%. It offers kits for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The company has been able to introduce innovative products, such as Abbott RealTime IDH1 and Abbott RealTime IDH2 assay kits, into the market.


F. Hoffmann-La Roche was the second-largest player in the hemato-oncology testing market. The company offers a full range of tests for the diagnosis of hemato-oncology cancers, such as leukemia, lymphoma, myeloma, and other cancers. Its strong presence across the globe, robust distribution channels, and brand image help the company maintain a dominant position in the hemato-oncology testing market. Roche has been focusing on emerging markets in recent years, with specific focus on the Asia Pacific.


QIAGEN was the third-largest player in this market in 2021. The company offers the RT2 Profiler PCR arrays for testing hemato-oncology cancers. It focuses on organic growth strategies to maintain its leading position in the market. In 2021, the company launched the QIAact Myeloid DNA UMI Panel for hemato-oncology cancer research. The company also focuses on R&D to introduce innovative products into the market.

Curious about this latest version of the report? Obtain Report Details @ https://www.marketsandmarkets.com/Market-Reports/hemato-oncology-testing-market-262472877.html

Market Segmentation

This research report categorizes the hemato oncology testing market based on Product and Services type, Cancer type, technology, and region.

By Product & Service

  • Services
  • Assay Kits

By Cancer Type

  • Introduction
  • Leukemia
  • lymphoma
  • Other cancers

By Technology

  • Introduction
  • PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others Technologies

by End User

  • Introduction
  • Clinical laboratories
  • Hospitals
  • Academic & Research Institutes
  • Other End Users

By Region

  • Introduction
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Purchase This Market Research Report @  https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=262472877

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/hemato-oncology-testing-market-262472877.html